MATK up 18% on 8-K.
8-K: MARTEK BIOSCIENCES CORP
(EDGAR Online via COMTEX) --
-------------------------------------------------------------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 8, 2006
Martek Biosciences Corporation __________________________________________ (Exact name of registrant as specified in its charter)
Delaware 0-22354 52-1399362 _____________________ _____________ ______________ (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 6480 Dobbin Road, Columbia, Maryland 21045 _________________________________ ___________ (Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 410-740-0081
Not Applicable ______________________________________________ Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-------------------------------------------------------------------------------- Top of the Form
Item 7.01 Regulation FD Disclosure.
Martek’s revenues for the first quarter of fiscal 2006 are expected to be between $62 and $63 million compared to previously projected first quarter revenues of $58 to $59 million. These first quarter revenues represent growth in sales to core infant formula customers.
As previously disclosed, in February 2005, we entered into a DHA license and supply agreement with a major consumer packaged goods company. There are no minimum purchase requirements or financial commitments to us under the agreement and we have not recognized any material revenues under it to date. Since entering into the agreement, Martek has been working closely with the food company on product development efforts. Based on recent discussions with the food company and progress to date on these development efforts, Martek currently believes that, while subject to final product selection, food formulation and consumer testing, the food company now projects that the initial product launch of a food containing Martek DHA will take place in 2007.
In addition, Martek expects that another major consumer packaged goods company will be announcing and making the commercial introduction of a consumer food/ beverage product containing Martek’s DHA in the first quarter of calendar 2006.
-------------------------------------------------------------------------------- Top of the Form
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Martek Biosciences Corporation February 8, 2006 By: /s/ George P. Barker ---------------------------------- Name: George P. Barker Title: Senior Vice President, General Counsel and Secretary |
